Edaravone in the treatment of amyotrophic lateral sclerosis
Saved in:
| Published in | Neurologia i neurochirurgia polska Vol. 52; no. 2; pp. 124 - 128 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Poland
Elsevier Urban & Partner Sp. z o.o
01.03.2018
Wydawnictwo Via Medica |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0028-3843 1897-4260 |
| DOI | 10.1016/j.pjnns.2018.03.004 |
Cover
| Author | Kuźma-Kozakiewicz, Magdalena |
|---|---|
| Author_xml | – sequence: 1 givenname: Magdalena surname: Kuźma-Kozakiewicz fullname: Kuźma-Kozakiewicz, Magdalena organization: Department of Neurology, Medical University of Warsaw, Warsaw, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29571701$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkE1r3DAQQEVJaTZpf0GhGHrpxc7ow7ZM6aGEJA0EeknOYlYeExlb2kraQP59lWzaQw7tSZf3ZkbvhB354ImxjxwaDrw7m5vd7H1qBHDdgGwA1Bu24XroayU6OGIbAKFrqZU8ZicpzQVoW4B37FgMbc974Bv29WLEiA9lcuV8le-pypEwr-RzFaYK18eQY9jdO1stmCniUiW7UAzJpffs7YRLog8v7ym7u7y4Pf9R3_y8uj7_flNbqWWuUdltNynRjqhU33HkVlmLvZg47yctEXir-RZJa-h5C4iF6eSEeqsm7K08ZV8Oc3cx_NpTymZ1ydKyoKewT-YpAIhhELKgn1-hc9hHX64zQnVKCAm9KNSnF2q_XWk0u-hWjI_mT5YCyANgy0dTpOkvwsE8xTezeY7_vNuANKVtsYZXlnUZsws-R3TLf9xvB5dKyAdH0STryFsaXSSbzRjcP_3flkaftQ |
| CitedBy_id | crossref_primary_10_1016_j_isci_2022_105898 crossref_primary_10_1007_s11302_018_9633_4 crossref_primary_10_1248_bpb_b24_00794 crossref_primary_10_2174_1566524020666200427214356 |
| Cites_doi | 10.1080/21678421.2017.1369125 10.1080/21678421.2017.1361443 10.15585/mmwr.ss6508a1 10.3164/jcbn.17-62 10.1016/j.pmr.2008.04.005 10.1080/21678421.2017.1353100 10.1080/21678421.2017.1353101 10.1186/1750-1172-4-3 10.1016/S1474-4422(17)30289-2 10.1080/21678421.2017.1361445 10.1080/21678421.2017.1362440 10.1016/B978-0-12-802973-2.00013-6 10.1016/S1474-4422(17)30115-1 10.1038/nature20413 10.1080/21678421.2017.1361446 10.3109/21678421.2014.959024 10.1080/21678421.2017.1365372 |
| ContentType | Journal Article |
| Copyright | 2018 2018. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2018 – notice: 2018. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M2M NAPCQ PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1016/j.pjnns.2018.03.004 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1897-4260 |
| EndPage | 128 |
| ExternalDocumentID | 29571701 10_1016_j_pjnns_2018_03_004 S002838431830080X |
| Genre | Editorial Commentary |
| GroupedDBID | --M 0R~ 123 29N 2WC 4.4 457 53G 7-5 7RV 7X7 8FI 8FJ 8P~ AAEDT AAIKJ AALRI AAOAW AAXLA AAXUO ABMXE ABMZM ABUWG ABXDB ABYKQ ADBBV ADEZE AEKER AENEX AFKRA AGHFR AITUG AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW ANZVX AZQEC BENPR BLXMC CCPQU DWQXO E3Z EBS EFLBG EJD EMOBN F5P FDB FEDTE FIRID FYUFA GBLVA GNUQQ HMCUK HVGLF HZ~ M2M NAPCQ O9- OAUVE OK1 PIMPY PSYQQ ROL T5K UKHRP W2D Y2W ZGI ZXP AAYXX ALIPV CITATION OVT PHGZM PHGZT CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c383t-a4cb6f425da44761a1c4cca72f117f83a01581bae8807150aa61a63fa8b4fa7c3 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-3843 |
| IngestDate | Fri Sep 05 02:42:53 EDT 2025 Fri Jul 25 07:43:36 EDT 2025 Wed Feb 19 02:36:33 EST 2025 Thu Apr 24 23:03:50 EDT 2025 Tue Jul 01 02:27:50 EDT 2025 Fri Feb 23 02:35:43 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c383t-a4cb6f425da44761a1c4cca72f117f83a01581bae8807150aa61a63fa8b4fa7c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1 |
| OpenAccessLink | https://www.proquest.com/docview/2464223072?pq-origsite=%requestingapplication% |
| PMID | 29571701 |
| PQID | 2464223072 |
| PQPubID | 2028858 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_2018029923 proquest_journals_2464223072 pubmed_primary_29571701 crossref_primary_10_1016_j_pjnns_2018_03_004 crossref_citationtrail_10_1016_j_pjnns_2018_03_004 elsevier_sciencedirect_doi_10_1016_j_pjnns_2018_03_004 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-03-01 |
| PublicationDateYYYYMMDD | 2018-03-01 |
| PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Poland |
| PublicationPlace_xml | – name: Poland – name: Kraków |
| PublicationTitle | Neurologia i neurochirurgia polska |
| PublicationTitleAlternate | Neurol Neurochir Pol |
| PublicationYear | 2018 |
| Publisher | Elsevier Urban & Partner Sp. z o.o Wydawnictwo Via Medica |
| Publisher_xml | – name: Elsevier Urban & Partner Sp. z o.o – name: Wydawnictwo Via Medica |
| References | (bib0060) May 2017 (bib0085) 2017; 18 Takei, Takahashi, Liu, Tsuda, Palumbo (bib0110) 2017; 18 Maragakis (bib0130) 2017; 18 Talbott, Malek, Lacomis (bib0025) 2016; 138 Kalin, Medina-Paraiso, Ishizaki, Kim, Zhang, Saita (bib0120) 2017; 18 Abe, Itoyama, Sobue, Tsuji, Aoki, Doyu (bib0070) 2014; 15 Takei, Watanabe, Yuki, Akimoto, Sakata, Palumbo (bib0055) 2017; 18 Al-Chalabi, Andersen, Chandran, Chio, Corcia, Couratier (bib0095) 2017; 18 Silani, Ludolph, Fornai (bib0135) 2017; 155 Cruz (bib0050) 2018; 43 (bib0040) 2017; 16 Mora (bib0100) 2017; 16 Takei, Tsuda, Takahashi, Hirai, Palumbo (bib0105) 2017; 18 Yeo, Simmons (bib0125) 2018; 15 Mehta, Kaye, Bryan, Larson, Copeland, Wu (bib0010) 2016; 65 Nakamaru, Kinoshita, Kawaguchi, Takei, Palumbo, Suzuki (bib0065) 2017; 18 (bib0075) 2017; 18 (bib0090) 2017; 18 Miller, Mitchell, Lyon, Moore (bib0035) 2007; 1 Watanabe, Tanaka, Yuki, Hirai, Yamamoto (bib0045) 2018; 62 Distad, Meekins, Liou, Weiss, Carter, Miller (bib0030) 2008; 19 (bib0080) 2017; 18 Takei, Tsuda, Takahashi, Palumbo (bib0115) 2017; 18 Wijesekera, Leigh (bib0015) 2009; 4 Taylor, Brown, Cleveland (bib0005) 2016; 539 Marin, Boumédiene, Logroscino, Couratier, Babron, Leutenegger (bib0020) 2017; 46 Kalin (10.1016/j.pjnns.2018.03.004_bib0120) 2017; 18 (10.1016/j.pjnns.2018.03.004_bib0085) 2017; 18 (10.1016/j.pjnns.2018.03.004_bib0040) 2017; 16 Wijesekera (10.1016/j.pjnns.2018.03.004_bib0015) 2009; 4 (10.1016/j.pjnns.2018.03.004_bib0080) 2017; 18 (10.1016/j.pjnns.2018.03.004_bib0075) 2017; 18 Takei (10.1016/j.pjnns.2018.03.004_bib0110) 2017; 18 Miller (10.1016/j.pjnns.2018.03.004_bib0035) 2007; 1 (10.1016/j.pjnns.2018.03.004_bib0090) 2017; 18 Al-Chalabi (10.1016/j.pjnns.2018.03.004_bib0095) 2017; 18 Nakamaru (10.1016/j.pjnns.2018.03.004_bib0065) 2017; 18 Takei (10.1016/j.pjnns.2018.03.004_bib0115) 2017; 18 Takei (10.1016/j.pjnns.2018.03.004_bib0055) 2017; 18 Mora (10.1016/j.pjnns.2018.03.004_bib0100) 2017; 16 Watanabe (10.1016/j.pjnns.2018.03.004_bib0045) 2018; 62 Marin (10.1016/j.pjnns.2018.03.004_bib0020) 2017; 46 Talbott (10.1016/j.pjnns.2018.03.004_bib0025) 2016; 138 Abe (10.1016/j.pjnns.2018.03.004_bib0070) 2014; 15 Maragakis (10.1016/j.pjnns.2018.03.004_bib0130) 2017; 18 Silani (10.1016/j.pjnns.2018.03.004_bib0135) 2017; 155 (10.1016/j.pjnns.2018.03.004_bib0060) 2017 Distad (10.1016/j.pjnns.2018.03.004_bib0030) 2008; 19 Yeo (10.1016/j.pjnns.2018.03.004_bib0125) 2018; 15 Takei (10.1016/j.pjnns.2018.03.004_bib0105) 2017; 18 Cruz (10.1016/j.pjnns.2018.03.004_bib0050) 2018; 43 Mehta (10.1016/j.pjnns.2018.03.004_bib0010) 2016; 65 Taylor (10.1016/j.pjnns.2018.03.004_bib0005) 2016; 539 |
| References_xml | – volume: 18 start-page: 98 year: 2017 end-page: 103 ident: bib0130 article-title: What can we learn from the edaravone development program for ALS? publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 138 start-page: 225 year: 2016 end-page: 238 ident: bib0025 article-title: The epidemiology of amyotrophic lateral sclerosis publication-title: Handb Clin Neurol – volume: 16 start-page: 505 year: 2017 end-page: 512 ident: bib0040 article-title: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial publication-title: Lancet Neurol – volume: 19 start-page: 633 year: 2008 end-page: 651 ident: bib0030 article-title: Drug therapy in amyotrophic lateral sclerosis publication-title: Phys Med Rehabil Clin N Am – volume: 18 start-page: 49 year: 2017 end-page: 54 ident: bib0110 article-title: Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 46 start-page: 57 year: 2017 end-page: 74 ident: bib0020 article-title: Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis publication-title: Int J Epidemiol – volume: 18 start-page: 11 year: 2017 end-page: 19 ident: bib0085 article-title: A post hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 15 start-page: 1 year: 2018 end-page: 6 ident: bib0125 article-title: Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 471 year: 2017 end-page: 474 ident: bib0095 article-title: July 2017 ENCALS statement on edaravone publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 155 start-page: 99 year: 2017 end-page: 109 ident: bib0135 article-title: The emerging picture of ALS: a multisystem, not only a motor neuron disease publication-title: Arch Ital Biol – volume: 18 start-page: 64 year: 2017 end-page: 70 ident: bib0115 article-title: Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateralsclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – year: May 2017 ident: bib0060 article-title: Radicava (edaravone) prescribing information – volume: 18 start-page: 71 year: 2017 end-page: 79 ident: bib0120 article-title: A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in threerandomized, placebo-controlled studies publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 62 start-page: 20 year: 2018 end-page: 38 ident: bib0045 article-title: How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? publication-title: J Clin Biochem Nutr – volume: 18 start-page: 80 year: 2017 end-page: 87 ident: bib0065 article-title: Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 5 year: 2017 end-page: 10 ident: bib0055 article-title: Edaravone and its clinical development for amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 88 year: 2017 end-page: 97 ident: bib0105 article-title: An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 55 year: 2017 end-page: 63 ident: bib0080 article-title: Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 539 start-page: 197 year: 2016 end-page: 206 ident: bib0005 article-title: Decoding ALS: from genes to mechanism publication-title: Nature – volume: 15 start-page: 610 year: 2014 end-page: 617 ident: bib0070 article-title: Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 43 start-page: 25 year: 2018 end-page: 28 ident: bib0050 article-title: Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis publication-title: P T – volume: 65 start-page: 1 year: 2016 end-page: 12 ident: bib0010 article-title: Prevalence of amyotrophic lateral sclerosis – United States, 2012–2013 publication-title: MMWR Surveill Summ – volume: 1 start-page: CD001447 year: 2007 ident: bib0035 article-title: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) publication-title: Cochrane Database Syst Rev – volume: 4 start-page: 3 year: 2009 ident: bib0015 article-title: Amyotroph lateral scler publication-title: Orph J Rare Dis – volume: 18 start-page: 20 year: 2017 end-page: 31 ident: bib0075 article-title: Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 16 start-page: 772 year: 2017 ident: bib0100 article-title: Edaravone for treatment of early-stage ALS publication-title: Lancet Neurol – volume: 18 start-page: 40 year: 2017 end-page: 48 ident: bib0090 article-title: Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation) publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 471 issue: 7–8 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0095 article-title: July 2017 ENCALS statement on edaravone publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1369125 – volume: 155 start-page: 99 issue: 4 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0135 article-title: The emerging picture of ALS: a multisystem, not only a motor neuron disease publication-title: Arch Ital Biol – volume: 18 start-page: 49 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0110 article-title: Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1361443 – volume: 65 start-page: 1 year: 2016 ident: 10.1016/j.pjnns.2018.03.004_bib0010 article-title: Prevalence of amyotrophic lateral sclerosis – United States, 2012–2013 publication-title: MMWR Surveill Summ doi: 10.15585/mmwr.ss6508a1 – volume: 62 start-page: 20 issue: 1 year: 2018 ident: 10.1016/j.pjnns.2018.03.004_bib0045 article-title: How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? publication-title: J Clin Biochem Nutr doi: 10.3164/jcbn.17-62 – volume: 19 start-page: 633 issue: 3 year: 2008 ident: 10.1016/j.pjnns.2018.03.004_bib0030 article-title: Drug therapy in amyotrophic lateral sclerosis publication-title: Phys Med Rehabil Clin N Am doi: 10.1016/j.pmr.2008.04.005 – volume: 18 start-page: 80 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0065 article-title: Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1353100 – volume: 18 start-page: 5 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0055 article-title: Edaravone and its clinical development for amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1353101 – volume: 15 start-page: 1 year: 2018 ident: 10.1016/j.pjnns.2018.03.004_bib0125 article-title: Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 4 start-page: 3 year: 2009 ident: 10.1016/j.pjnns.2018.03.004_bib0015 article-title: Amyotroph lateral scler publication-title: Orph J Rare Dis doi: 10.1186/1750-1172-4-3 – volume: 16 start-page: 772 issue: 10 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0100 article-title: Edaravone for treatment of early-stage ALS publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30289-2 – volume: 18 start-page: 88 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0105 article-title: An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1361445 – volume: 18 start-page: 55 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0080 article-title: Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 11 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0085 article-title: A post hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 71 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0120 article-title: A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in threerandomized, placebo-controlled studies publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1362440 – volume: 138 start-page: 225 year: 2016 ident: 10.1016/j.pjnns.2018.03.004_bib0025 article-title: The epidemiology of amyotrophic lateral sclerosis publication-title: Handb Clin Neurol doi: 10.1016/B978-0-12-802973-2.00013-6 – year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0060 – volume: 46 start-page: 57 issue: February (1) year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0020 article-title: Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis publication-title: Int J Epidemiol – volume: 16 start-page: 505 issue: 7 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0040 article-title: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30115-1 – volume: 43 start-page: 25 issue: 1 year: 2018 ident: 10.1016/j.pjnns.2018.03.004_bib0050 article-title: Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis publication-title: P T – volume: 18 start-page: 20 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0075 article-title: Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 18 start-page: 40 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0090 article-title: Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation) publication-title: Amyotroph Lateral Scler Frontotemporal Degener – volume: 539 start-page: 197 issue: November (7628) year: 2016 ident: 10.1016/j.pjnns.2018.03.004_bib0005 article-title: Decoding ALS: from genes to mechanism publication-title: Nature doi: 10.1038/nature20413 – volume: 18 start-page: 98 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0130 article-title: What can we learn from the edaravone development program for ALS? publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1361446 – volume: 15 start-page: 610 issue: 7–8 year: 2014 ident: 10.1016/j.pjnns.2018.03.004_bib0070 article-title: Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.3109/21678421.2014.959024 – volume: 18 start-page: 64 issue: Suppl. 1 year: 2017 ident: 10.1016/j.pjnns.2018.03.004_bib0115 article-title: Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateralsclerosis publication-title: Amyotroph Lateral Scler Frontotemporal Degener doi: 10.1080/21678421.2017.1365372 – volume: 1 start-page: CD001447 issue: January year: 2007 ident: 10.1016/j.pjnns.2018.03.004_bib0035 article-title: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) publication-title: Cochrane Database Syst Rev |
| SSID | ssj0045500 |
| Score | 2.122929 |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 124 |
| SubjectTerms | Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - drug therapy Double-Blind Method Edaravone - therapeutic use Humans |
| Title | Edaravone in the treatment of amyotrophic lateral sclerosis |
| URI | https://dx.doi.org/10.1016/j.pjnns.2018.03.004 https://www.ncbi.nlm.nih.gov/pubmed/29571701 https://www.proquest.com/docview/2464223072 https://www.proquest.com/docview/2018029923 |
| Volume | 52 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_8APFF_HY6JYKPFtska1J8EJUNERQRhb2FNG1wY7Zzm4L_vZc27Zt7TnKEu1zul-TyO4CLSMYZ1YIGIU9lwHMqA4zzJhB5mHFOjUgqSz89xw_v_HHYG_oLt7lPq2z2xGqjzkrj7sivKEek7LKW6c30K3BVo9zrqi-hsQrrESIRV7pBDNsDl_uwGzYszExy1rAOVfld03FROL7uSNYsp_y_yPQf8qwi0GAbtjx0JLe1rXdgJS92YePJP47vwXU_0zP9UxY5GRUEgR1ps8hJaYn-_C0Xs3L6MTJkot3H4wmZoyCczGi-D--D_tv9Q-BrIwQGz5SLQHOTxhYdLtOcizjSkeFoDEFtFAkrmcYwj4hU5-ifAkGf1tgnZlbLlFstDDuAtQIndAQkDK3IejpJMp5wa-KEM2pDaXPKUimY7QBt9KKMJw539SsmqskQG6tKmcopU4VMoTI7cNkOmta8Gcu7x43ClQ_9dUhXuLMvH9htzKO892F7u1Y6cN42o9-4xxBd5OV3LSPEWExZBw5rs7YTpUlPOJ764-XCT2DTSakz0rqwtph956cIURbpWbUOz2D9rv_88voHAf3j_w |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEN8UBhgJ3ohIbDd2hCbER6eOrRVCm7Q34zi26FSS0nag_XP8bZwTO2_r255jn5y7s-9n-_w7gNeZzCuqBU1SXsqEWyoTjPMmETatOKdGFK2lp7N8csq_no3OduBffAvj0yrjmtgu1FVj_Bn5O8oRKfusZfph-TvxVaP87WosoaFDaYVqv6UYCw87juzlX9zCrfcPv6C931B6MD75PElClYHE4O5sk2huytyh61aac9zU68xw_C1BXZYJJ5nGgInYTlv0dIHwSWtskzOnZcmdFoah3Buwy_0BygB2P41n377HWOCfDKeRB5pJziLvUZthtjyva88YnsmOZ5VfFRuvwr5tDDy4C3cCeCUfO2-7Bzu2vg83p-F6_gG8H1d6pf80tSXzmiC0JH0eO2kc0b8um82qWf6cG7LQ_unzgqxREA5mvn4Ip9eit0cwqHFAT4CkqRPVSBdFxQvuTF5wRl0qnaWslIK5IdCoF2UCdbmvoLFQMUftXLXKVF6ZKmUKlTmEt32nZcfcsb15HhWuAvjoQIXC2LK94140jwrzH7_33jqEV_1nnLn-OkbXtrnoZKSIBigbwuPOrP1AaTESnin_6XbhL-HW5GR6rI4PZ0fP4LaX2OXH7cFgs7qwzxEwbcoXwSsJ_LjuifAfeD4mNg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Edaravone+in+the+treatment+of+amyotrophic+lateral+sclerosis&rft.jtitle=Neurologia+i+neurochirurgia+polska&rft.au=Ku%C5%BAma-Kozakiewicz%2C+Magdalena&rft.date=2018-03-01&rft.issn=0028-3843&rft.volume=52&rft.issue=2&rft.spage=124&rft_id=info:doi/10.1016%2Fj.pjnns.2018.03.004&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-3843&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-3843&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-3843&client=summon |